Supplementary Table S7 from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial

Summary of detected above the NCI-MATCH cut off (VAF ≥5% and 10% for SNV and Indel respectively) and reported SNV/Indel by assay (both assays, Central Lab (CL) or assay H only, DL assay only). For both detected and reported variants, positive percent agreement (PPA) with DL and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated.